Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab.

Next Previous
Trial Profile

Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Mar 2012 Actual end date (31 Mar 2011) added as reported by European Clinical Trials Database.
  • 29 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
  • 27 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top